Global Non-muscle Invasive Bladder Cancer Therapeutics Market Growth (Status and Outlook) 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2017-2028

2.1.2 Non-muscle Invasive Bladder Cancer Therapeutics Market Size CAGR by Region 2017 VS 2022 VS 2028

2.2 Non-muscle Invasive Bladder Cancer Therapeutics Segment by Type

2.2.1 Intravesical Chemotherapy

2.2.2 Intravesical Immunotherapy

2.3 Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type

2.3.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Size CAGR by Type (2017 VS 2022 VS 2028)

2.3.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type (2017-2022)

2.4 Non-muscle Invasive Bladder Cancer Therapeutics Segment by Application

2.4.1 Hospital

2.4.2 Ambulatory Surgery Center

2.4.3 Others

2.5 Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application

2.5.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Size CAGR by Application (2017 VS 2022 VS 2028)

2.5.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application (2017-2022)

3 Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Player

3.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Players

3.1.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Players (2020-2022)

3.1.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Players (2020-2022)

3.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 Non-muscle Invasive Bladder Cancer Therapeutics by Regions

4.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Regions (2017-2022)

4.2 Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth (2017-2022)

4.3 APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth (2017-2022)

4.4 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth (2017-2022)

4.5 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth (2017-2022)

5 Americas

5.1 Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2017-2022)

5.2 Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2017-2022)

5.3 Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2017-2022)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2017-2022)

6.2 APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2017-2022)

6.3 APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2017-2022)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe Non-muscle Invasive Bladder Cancer Therapeutics by Country (2017-2022)

7.2 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2017-2022)

7.3 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2017-2022)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics by Region (2017-2022)

8.2 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2017-2022)

8.3 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2017-2022)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecast by Regions (2023-2028)

10.1.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecast by Regions (2023-2028)

10.1.2 Americas Non-muscle Invasive Bladder Cancer Therapeutics Forecast

10.1.3 APAC Non-muscle Invasive Bladder Cancer Therapeutics Forecast

10.1.4 Europe Non-muscle Invasive Bladder Cancer Therapeutics Forecast

10.1.5 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Forecast

10.2 Americas Non-muscle Invasive Bladder Cancer Therapeutics Forecast by Country (2023-2028)

10.2.1 United States Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.2.2 Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.2.3 Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.2.4 Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.3 APAC Non-muscle Invasive Bladder Cancer Therapeutics Forecast by Region (2023-2028)

10.3.1 China Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.3.2 Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.3.3 Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.3.4 Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.3.5 India Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.3.6 Australia Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.4 Europe Non-muscle Invasive Bladder Cancer Therapeutics Forecast by Country (2023-2028)

10.4.1 Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.4.2 France Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.4.3 UK Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.4.4 Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.4.5 Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.5 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Forecast by Region (2023-2028)

10.5.1 Egypt Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.5.2 South Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.5.3 Israel Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.5.4 Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.5.5 GCC Countries Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast

10.6 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecast by Type (2023-2028)

10.7 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecast by Application (2023-2028)

11 Key Players Analysis

11.1 F. Hoffmann-La Roche Ltd.

11.1.1 F. Hoffmann-La Roche Ltd. Company Information

11.1.2 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.1.4 F. Hoffmann-La Roche Ltd. Main Business Overview

11.1.5 F. Hoffmann-La Roche Ltd. Latest Developments

11.2 Bristol-Myers Squibb Company

11.2.1 Bristol-Myers Squibb Company Company Information

11.2.2 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.2.4 Bristol-Myers Squibb Company Main Business Overview

11.2.5 Bristol-Myers Squibb Company Latest Developments

11.3 AstraZeneca

11.3.1 AstraZeneca Company Information

11.3.2 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.3.4 AstraZeneca Main Business Overview

11.3.5 AstraZeneca Latest Developments

11.4 Pfizer Inc.

11.4.1 Pfizer Inc. Company Information

11.4.2 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.4.4 Pfizer Inc. Main Business Overview

11.4.5 Pfizer Inc. Latest Developments

11.5 GlaxoSmithKline plc.

11.5.1 GlaxoSmithKline plc. Company Information

11.5.2 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.5.4 GlaxoSmithKline plc. Main Business Overview

11.5.5 GlaxoSmithKline plc. Latest Developments

11.6 Sanofi S.A.

11.6.1 Sanofi S.A. Company Information

11.6.2 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.6.4 Sanofi S.A. Main Business Overview

11.6.5 Sanofi S.A. Latest Developments

11.7 Novartis AG

11.7.1 Novartis AG Company Information

11.7.2 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.7.4 Novartis AG Main Business Overview

11.7.5 Novartis AG Latest Developments

11.8 Eli Lilly and Company

11.8.1 Eli Lilly and Company Company Information

11.8.2 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.8.4 Eli Lilly and Company Main Business Overview

11.8.5 Eli Lilly and Company Latest Developments

11.9 Merck & Co.

11.9.1 Merck & Co. Company Information

11.9.2 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.9.4 Merck & Co. Main Business Overview

11.9.5 Merck & Co. Latest Developments

11.10 Viventia Bio Inc.

11.10.1 Viventia Bio Inc. Company Information

11.10.2 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.10.4 Viventia Bio Inc. Main Business Overview

11.10.5 Viventia Bio Inc. Latest Developments

11.11 Celgene Corporation

11.11.1 Celgene Corporation Company Information

11.11.2 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.11.4 Celgene Corporation Main Business Overview

11.11.5 Celgene Corporation Latest Developments

11.12 Spectrum Pharmaceuticals, Inc.

11.12.1 Spectrum Pharmaceuticals, Inc. Company Information

11.12.2 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.12.4 Spectrum Pharmaceuticals, Inc. Main Business Overview

11.12.5 Spectrum Pharmaceuticals, Inc. Latest Developments

11.13 Herantis Pharma Plc.

11.13.1 Herantis Pharma Plc. Company Information

11.13.2 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.13.4 Herantis Pharma Plc. Main Business Overview

11.13.5 Herantis Pharma Plc. Latest Developments

11.14 Taris Biomedical LLC

11.14.1 Taris Biomedical LLC Company Information

11.14.2 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.14.4 Taris Biomedical LLC Main Business Overview

11.14.5 Taris Biomedical LLC Latest Developments

11.15 Prometic Life Sciences Inc.

11.15.1 Prometic Life Sciences Inc. Company Information

11.15.2 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.15.4 Prometic Life Sciences Inc. Main Business Overview

11.15.5 Prometic Life Sciences Inc. Latest Developments

11.16 Telormediz S.A.

11.16.1 Telormediz S.A. Company Information

11.16.2 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.16.4 Telormediz S.A. Main Business Overview

11.16.5 Telormediz S.A. Latest Developments

11.17 Heat Biologics

11.17.1 Heat Biologics Company Information

11.17.2 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.17.4 Heat Biologics Main Business Overview

11.17.5 Heat Biologics Latest Developments

11.18 Altor BioScience

11.18.1 Altor BioScience Company Information

11.18.2 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.18.4 Altor BioScience Main Business Overview

11.18.5 Altor BioScience Latest Developments

11.19 Ferring B.V.

11.19.1 Ferring B.V. Company Information

11.19.2 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.19.4 Ferring B.V. Main Business Overview

11.19.5 Ferring B.V. Latest Developments

11.20 Cold Genesys Inc.

11.20.1 Cold Genesys Inc. Company Information

11.20.2 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

11.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2022)

11.20.4 Cold Genesys Inc. Main Business Overview

11.20.5 Cold Genesys Inc. Latest Developments

12 Research Findings and Conclusion

Table 1. Non-muscle Invasive Bladder Cancer Therapeutics Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)

Table 2. Major Players of Intravesical Chemotherapy

Table 3. Major Players of Intravesical Immunotherapy

Table 4. Non-muscle Invasive Bladder Cancer Therapeutics Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)

Table 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2017-2022) & ($ Millions)

Table 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type (2017-2022)

Table 7. Non-muscle Invasive Bladder Cancer Therapeutics Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)

Table 8. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2017-2022) & ($ Millions)

Table 9. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application (2017-2022)

Table 10. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Players (2020-2022) & ($ Millions)

Table 11. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Player (2020-2022)

Table 12. Non-muscle Invasive Bladder Cancer Therapeutics Key Players Head office and Products Offered

Table 13. Non-muscle Invasive Bladder Cancer Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Regions 2017-2022 & ($ Millions)

Table 17. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Regions (2017-2022)

Table 18. Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2017-2022) & ($ Millions)

Table 19. Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Country (2017-2022)

Table 20. Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2017-2022) & ($ Millions)

Table 21. Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type (2017-2022)

Table 22. Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2017-2022) & ($ Millions)

Table 23. Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application (2017-2022)

Table 24. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2017-2022) & ($ Millions)

Table 25. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Region (2017-2022)

Table 26. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2017-2022) & ($ Millions)

Table 27. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type (2017-2022)

Table 28. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2017-2022) & ($ Millions)

Table 29. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application (2017-2022)

Table 30. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2017-2022) & ($ Millions)

Table 31. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Country (2017-2022)

Table 32. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2017-2022) & ($ Millions)

Table 33. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type (2017-2022)

Table 34. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2017-2022) & ($ Millions)

Table 35. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application (2017-2022)

Table 36. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2017-2022) & ($ Millions)

Table 37. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Region (2017-2022)

Table 38. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2017-2022) & ($ Millions)

Table 39. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type (2017-2022)

Table 40. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2017-2022) & ($ Millions)

Table 41. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application (2017-2022)

Table 42. Key Market Drivers & Growth Opportunities of Non-muscle Invasive Bladder Cancer Therapeutics

Table 43. Key Market Challenges & Risks of Non-muscle Invasive Bladder Cancer Therapeutics

Table 44. Key Industry Trends of Non-muscle Invasive Bladder Cancer Therapeutics

Table 45. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Forecast by Regions (2023-2028) & ($ Millions)

Table 46. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share Forecast by Regions (2023-2028)

Table 47. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Forecast by Type (2023-2028) & ($ Millions)

Table 48. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share Forecast by Type (2023-2028)

Table 49. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Forecast by Application (2023-2028) & ($ Millions)

Table 50. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share Forecast by Application (2023-2028)

Table 51. F. Hoffmann-La Roche Ltd. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 52. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 53. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 54. F. Hoffmann-La Roche Ltd. Main Business

Table 55. F. Hoffmann-La Roche Ltd. Latest Developments

Table 56. Bristol-Myers Squibb Company Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 57. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 58. Bristol-Myers Squibb Company Main Business

Table 59. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 60. Bristol-Myers Squibb Company Latest Developments

Table 61. AstraZeneca Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 62. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 63. AstraZeneca Main Business

Table 64. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 65. AstraZeneca Latest Developments

Table 66. Pfizer Inc. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 67. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 68. Pfizer Inc. Main Business

Table 69. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 70. Pfizer Inc. Latest Developments

Table 71. GlaxoSmithKline plc. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 72. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 73. GlaxoSmithKline plc. Main Business

Table 74. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 75. GlaxoSmithKline plc. Latest Developments

Table 76. Sanofi S.A. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 77. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 78. Sanofi S.A. Main Business

Table 79. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 80. Sanofi S.A. Latest Developments

Table 81. Novartis AG Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 82. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 83. Novartis AG Main Business

Table 84. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 85. Novartis AG Latest Developments

Table 86. Eli Lilly and Company Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 87. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 88. Eli Lilly and Company Main Business

Table 89. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 90. Eli Lilly and Company Latest Developments

Table 91. Merck & Co. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 92. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 93. Merck & Co. Main Business

Table 94. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 95. Merck & Co. Latest Developments

Table 96. Viventia Bio Inc. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 97. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 98. Viventia Bio Inc. Main Business

Table 99. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 100. Viventia Bio Inc. Latest Developments

Table 101. Celgene Corporation Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 102. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 103. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 104. Celgene Corporation Main Business

Table 105. Celgene Corporation Latest Developments

Table 106. Spectrum Pharmaceuticals, Inc. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 107. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 108. Spectrum Pharmaceuticals, Inc. Main Business

Table 109. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 110. Spectrum Pharmaceuticals, Inc. Latest Developments

Table 111. Herantis Pharma Plc. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 112. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 113. Herantis Pharma Plc. Main Business

Table 114. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 115. Herantis Pharma Plc. Latest Developments

Table 116. Taris Biomedical LLC Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 117. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 118. Taris Biomedical LLC Main Business

Table 119. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 120. Taris Biomedical LLC Latest Developments

Table 121. Prometic Life Sciences Inc. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 122. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 123. Prometic Life Sciences Inc. Main Business

Table 124. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 125. Prometic Life Sciences Inc. Latest Developments

Table 126. Telormediz S.A. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 127. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 128. Telormediz S.A. Main Business

Table 129. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 130. Telormediz S.A. Latest Developments

Table 131. Heat Biologics Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 132. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 133. Heat Biologics Main Business

Table 134. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 135. Heat Biologics Latest Developments

Table 136. Altor BioScience Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 137. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 138. Altor BioScience Main Business

Table 139. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 140. Altor BioScience Latest Developments

Table 141. Ferring B.V. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 142. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 143. Ferring B.V. Main Business

Table 144. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 145. Ferring B.V. Latest Developments

Table 146. Cold Genesys Inc. Details, Company Type, Non-muscle Invasive Bladder Cancer Therapeutics Area Served and Its Competitors

Table 147. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offered

Table 148. Cold Genesys Inc. Main Business

Table 149. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 150. Cold Genesys Inc. Latest Developments

List of Figures

Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate 2017-2028 ($ Millions)

Figure 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type in 2021

Figure 7. Non-muscle Invasive Bladder Cancer Therapeutics in Hospital

Figure 8. Global Non-muscle Invasive Bladder Cancer Therapeutics Market: Hospital (2017-2022) & ($ Millions)

Figure 9. Non-muscle Invasive Bladder Cancer Therapeutics in Ambulatory Surgery Center

Figure 10. Global Non-muscle Invasive Bladder Cancer Therapeutics Market: Ambulatory Surgery Center (2017-2022) & ($ Millions)

Figure 11. Non-muscle Invasive Bladder Cancer Therapeutics in Others

Figure 12. Global Non-muscle Invasive Bladder Cancer Therapeutics Market: Others (2017-2022) & ($ Millions)

Figure 13. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application in 2021

Figure 14. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Player in 2021

Figure 15. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Regions (2017-2022)

Figure 16. Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2017-2022 ($ Millions)

Figure 17. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2017-2022 ($ Millions)

Figure 18. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2017-2022 ($ Millions)

Figure 19. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2017-2022 ($ Millions)

Figure 20. Americas Non-muscle Invasive Bladder Cancer Therapeutics Value Market Share by Country in 2021

Figure 21. Americas Non-muscle Invasive Bladder Cancer Therapeutics Consumption Market Share by Type in 2021

Figure 22. Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application in 2021

Figure 23. United States Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 24. Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 25. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 26. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 27. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Region in 2021

Figure 28. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application in 2021

Figure 29. China Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 30. Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 31. Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 32. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 33. India Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 34. Australia Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 35. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Country in 2021

Figure 36. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type in 2021

Figure 37. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application in 2021

Figure 38. Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 39. France Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 40. UK Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 41. Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 42. Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 43. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Region in 2021

Figure 44. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type in 2021

Figure 45. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application in 2021

Figure 46. Egypt Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 47. South Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 48. Israel Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 49. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 50. GCC Country Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth 2017-2022 ($ Millions)

Figure 51. Americas Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 52. APAC Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 53. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 54. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 55. United States Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 56. Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 57. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 58. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 59. China Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 60. Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 61. Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 62. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 63. India Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 64. Australia Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 65. Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 66. France Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 67. UK Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 68. Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 69. Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 70. Spain Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 71. Egypt Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 72. South Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 73. Israel Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 74. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)

Figure 75. GCC Countries Non-muscle Invasive Bladder Cancer Therapeutics Market Size 2023-2028 ($ Millions)